SCHEMBL30219969

SCHEMBL30219969

COCc1c[nH]c(=O)c2ccsc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 1/20 0.40
GSK3B P49841 1/20 0.40
PARP1 P09874 4/20 0.38
HTR2A P28223 2/20 0.35
HTR2C P28335 2/20 0.35
HTR2B P41595 2/20 0.35
HSD17B3 P37058 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
PARP15 Q460N3 1/20 0.33
PARP14 Q460N5 1/20 0.33
PARP10 Q53GL7 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
PARP2 Q9UGN5 1/20 0.33
PDPK1 O15530 1/20 0.33
NEK1 Q96PY6 7/20 0.32
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
CSNK2A2 P19784 1/20 0.32
CSNK2B P67870 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30219913 0.79 PARP1 (0.50) PARP1HTR2AHTR2CHTR2BADORA2A
SCHEMBL15716703 0.73 PARP1 (0.40) PARP1ADORA2AADORA1PARP15TNKS2
SCHEMBL30753217 0.71 NR4A2 (0.45) GSK3BKDM4E
SCHEMBL5240090 0.69 GSK3B (0.45) GSK3BPARP1ADORA2AADORA1PARP15
SCHEMBL22301763 0.69 PARP1 (0.37) PARP1ADORA2AADORA1PARP15TNKS2
SCHEMBL15092671 0.68 NEK1 (0.48) NEK1
SCHEMBL3069636 0.66 DPYD (0.42) CDK2GSK3BPARP1ADORA2AADORA1
SCHEMBL29196591 0.66 KDM4E (0.56) PARP1ADORA2AADORA1PARP15TNKS2
SCHEMBL30753226 0.65 NR4A2 (0.49) GSK3BKDM4E
SCHEMBL31484409 0.65 ALDH1A1 (0.41) PARP1ADORA2AADORA1PDPK1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162890-B2 Heteroaromatic NMDA receptor modulators and uses thereof NOVARTIS AG (CH) 2024-12-10 US disclosed
US-20230023543-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162890-B2 Heteroaromatic NMDA receptor modulators and uses thereof GRIN2C, GRIN2A, GRIN1 CDK2 783/4885GSK3B 2070/4885PARP1 3415/4885
US-20230023543-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN2C, GRIN2A, GRIN1 CDK2 783/4885GSK3B 2070/4885PARP1 3415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.